Composition of a series of prodrugs activated by HK2 enzyme to deliver a thapsigargin derivative selectively targeting prostate cancers is protected by the patent.
GenSpera CEO Craig Dionne said the patent strengthens intellectual property position for targeted anti-cancer prodrugs in addition to recognizing applicability in treating prostate cancer.
"It is important that we continue to expand and defend our thapsigargin prodrug research and development in areas of high unmet medical needs and commercial opportunities," Dionne added.
GenSpera’s lead drug candidate G-202 with 12ADT as the active component, which is a derivative of thapsigargin, is currently in Phase II clinical trials for liver cancer after sorafenib (Nexavar) therapy.
The company’s technology platform integrates plant-derived cytotoxin (thapsigargin) and prodrug delivery system for the targeted delivery of drug candidates within a tumor.